[go: up one dir, main page]

EE04489B1 - Atsüülpseudodipeptiidid, nende valmistamise meetod ja neid sisaldavad farmatseutilised kompositsioonid - Google Patents

Atsüülpseudodipeptiidid, nende valmistamise meetod ja neid sisaldavad farmatseutilised kompositsioonid

Info

Publication number
EE04489B1
EE04489B1 EEP200000791A EEP200000791A EE04489B1 EE 04489 B1 EE04489 B1 EE 04489B1 EE P200000791 A EEP200000791 A EE P200000791A EE P200000791 A EEP200000791 A EE P200000791A EE 04489 B1 EE04489 B1 EE 04489B1
Authority
EE
Estonia
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
pseudodipeptides
acyl
Prior art date
Application number
EEP200000791A
Other languages
English (en)
Inventor
Bauer Jacques
Richard Martin Olivier
Original Assignee
Om Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Om Pharma filed Critical Om Pharma
Publication of EE200000791A publication Critical patent/EE200000791A/et
Publication of EE04489B1 publication Critical patent/EE04489B1/et

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/10Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/091Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EEP200000791A 1998-06-30 1999-06-23 Atsüülpseudodipeptiidid, nende valmistamise meetod ja neid sisaldavad farmatseutilised kompositsioonid EE04489B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9801396 1998-06-30
PCT/IB1999/001170 WO2000000462A1 (fr) 1998-06-30 1999-06-23 Nouveaux pseudodipeptides acyles, leur mode de preparation et les compositions pharmaceutiques en renfermant

Publications (2)

Publication Number Publication Date
EE200000791A EE200000791A (et) 2002-02-15
EE04489B1 true EE04489B1 (et) 2005-06-15

Family

ID=9522667

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000791A EE04489B1 (et) 1998-06-30 1999-06-23 Atsüülpseudodipeptiidid, nende valmistamise meetod ja neid sisaldavad farmatseutilised kompositsioonid

Country Status (21)

Country Link
US (2) US7157092B1 (et)
EP (1) EP1091928B1 (et)
JP (1) JP4699609B2 (et)
KR (1) KR100766016B1 (et)
CN (1) CN1168702C (et)
AR (1) AR029877A1 (et)
AT (1) ATE355266T1 (et)
AU (1) AU761396B2 (et)
BR (1) BR9911329A (et)
CA (1) CA2337807C (et)
CZ (1) CZ302062B6 (et)
DE (1) DE69935330T2 (et)
DK (1) DK1091928T3 (et)
EE (1) EE04489B1 (et)
ES (1) ES2284275T3 (et)
HU (1) HUP0102475A3 (et)
PL (1) PL195764B1 (et)
RU (1) RU2223262C2 (et)
SK (1) SK287073B6 (et)
TW (1) TWI255808B (et)
WO (1) WO2000000462A1 (et)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0102475A3 (en) * 1998-06-30 2001-12-28 Om Pharma Novel acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same
WO2001046127A1 (fr) 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
JP2004529100A (ja) * 2001-01-30 2004-09-24 ユニバーシティ オブ バージニア パテント ファウンデーション スフィンゴシン−1−ホスフェートレセプターのアゴニストおよびアンタゴニスト
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
CA2487849A1 (en) 2002-07-18 2004-01-29 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
JP5022028B2 (ja) 2003-03-26 2012-09-12 サイトス・バイオテクノロジー・アクチェンゲゼルシャフト メラン−aペプチドアナログ−ウイルス様粒子コンジュゲート
ATE491467T1 (de) 2004-05-28 2011-01-15 Glaxosmithkline Biolog Sa Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
EA200701787A1 (ru) 2005-03-23 2008-08-29 Глаксосмитклайн Байолоджикалс С.А. Иммунная композиция, способ ее изготовления, ее применение и способ вакцинации
JP5484732B2 (ja) 2005-12-14 2014-05-07 サイトス バイオテクノロジー アーゲー 過敏症の治療のための免疫賦活性核酸パッケージ粒子
EP3020411A1 (en) 2005-12-22 2016-05-18 GlaxoSmithKline Biologicals s.a. Vaccine
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
JP5341526B2 (ja) * 2006-03-09 2013-11-13 オーエム ファーマ 免疫調節化合物、及び炎症性サイトカインの過剰産生に関連する疾患の治療
EA015833B1 (ru) 2006-03-30 2011-12-30 Глаксосмитклайн Байолоджикалс С.А. Иммуногенная композиция
SI2032592T1 (sl) 2006-06-12 2013-10-30 Cytos Biotechnology Ag Postopki za pakiranje oligonukleotidov v virusu-podobne delce RNA bakteriofagov
DK2043682T3 (da) 2006-07-17 2014-06-02 Glaxosmithkline Biolog Sa Influenzavaccine
EP2040743B1 (en) 2006-07-18 2013-10-02 GlaxoSmithKline Biologicals S.A. Vaccines for malaria
GB2453475B (en) 2006-07-25 2011-01-19 Secr Defence Live vaccine strain
SI2086582T1 (sl) 2006-10-12 2013-02-28 Glaxosmithkline Biologicals S.A. Cepivo, ki obsega emulzijo olja v vodi kot adjuvans
US20100055166A1 (en) 2007-03-02 2010-03-04 Gerald Hermann Voss Novel method and compositions
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
MX2009013949A (es) 2007-06-26 2010-05-24 Glaxosmithkline Biolog Sa Vacuna que comprende conjugados de polisacárido capsular de streptococcus pneumoniae.
EP2020240A1 (en) * 2007-07-30 2009-02-04 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Methods and substances for the treatment of Alzheimer's
PT2227483T (pt) 2007-12-19 2017-06-21 Henry M Jackson Found Advancement Military Medicine Inc Formas solúveis da glicoproteína f de vírus hendra e nipah e suas utilizações
EP4670734A2 (en) 2007-12-24 2025-12-31 GlaxoSmithKline Biologicals S.A. RECOMBINANT RSV ANTIGENS
MX2010011412A (es) 2008-04-16 2010-11-12 Glaxosmithkline Biolog Sa Vacuna.
EP2374813A1 (en) 2008-12-03 2011-10-12 Proyecto de Biomedicina Cima, S.L. Use of phenol-soluble modulins for vaccine development
WO2010079081A1 (en) 2009-01-07 2010-07-15 Glaxosmithkline Biologicals S.A. Methods for recovering a virus or a viral antigen produced by cell culture
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
CA2750055A1 (en) 2009-02-06 2010-08-12 Glaxosmithkline Biologicals S.A. Method for purifying viruses using a density gradient
SG2014014385A (en) 2009-02-17 2014-04-28 Glaxosmithkline Biolog Sa Inactivated dengue virus vaccine with aluminium-free adjuvant
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
EP2445527A2 (en) 2009-06-24 2012-05-02 ID Biomedical Corporation of Quebec Vaccine
PT2445526T (pt) 2009-06-24 2016-08-16 Glaxosmithkline Biologicals Sa Antigénios de rsv recombinantes
EP2453918B1 (en) 2009-07-15 2015-12-16 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
JP5774010B2 (ja) 2009-09-25 2015-09-02 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザウイルスのための免疫拡散アッセイ
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
WO2011101332A1 (en) 2010-02-16 2011-08-25 Proyecto De Biomedicina Cima, S.L. Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
CA2797059A1 (en) 2010-05-03 2011-11-10 Glaxosmithkline Biologicals S.A. Novel method
GB201009273D0 (en) 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
ES2635014T3 (es) 2010-10-15 2017-10-02 Glaxosmithkline Biologicals S.A. Antígeno gB del citomegalovirus
EP2505640A1 (en) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Vaccine compositions for birnavirus-borne diseases
US20140248314A1 (en) 2011-05-13 2014-09-04 Novartis Ag Pre-fusion rsv f antigens
KR20140033127A (ko) 2011-05-17 2014-03-17 글락소스미스클라인 바이오로지칼즈 에스.에이. 스트렙토코쿠스 뉴모니애에 대한 백신
CN104203270A (zh) 2012-03-18 2014-12-10 葛兰素史密丝克莱恩生物有限公司 针对人乳头状瘤病毒的接种方法
AU2013301312A1 (en) 2012-08-06 2015-03-19 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against RSV and B. pertussis
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
BE1022174B1 (fr) 2013-03-15 2016-02-24 Glaxosmithkline Biologicals S.A. Vaccin
ES3020582T3 (en) 2013-07-26 2025-05-23 Inst Nat Sante Rech Med Methods and pharmaceutical compositions for the treatment of bacterial infections
CN105555304A (zh) 2013-08-05 2016-05-04 葛兰素史密丝克莱恩生物有限公司 联合免疫原性组合物
JP6851827B2 (ja) 2013-08-30 2021-03-31 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 細胞培養中でのウイルスの大規模製造
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
EP3110401A4 (en) 2014-02-25 2017-10-25 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
WO2015165480A1 (en) 2014-04-30 2015-11-05 Institute For Research In Biomedicine Human cytomegalovirus vaccine compositions and method of producing the same
EP3888676A1 (en) 2014-06-13 2021-10-06 GlaxoSmithKline Biologicals S.A. Immunogenic combinations
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
US20180186897A1 (en) 2015-06-26 2018-07-05 Institute For Research In Biomedicine Novel vaccines in prevention and treatment of malaria
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
WO2018162450A1 (en) 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
EP3612562A2 (en) 2017-04-19 2020-02-26 Institute for Research in Biomedicine Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
EP3581201A1 (en) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 proteins and uses thereof
US11911553B2 (en) * 2018-07-06 2024-02-27 Fenwal, Inc. Systems and methods for concentrating cells with a syringe and a centrifuge
WO2021014385A1 (en) 2019-07-24 2021-01-28 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
CN112329267B (zh) * 2020-11-26 2022-08-16 中国核动力研究设计院 一种基于特征线法的组合几何中子输运处理方法及装置
WO2022117595A2 (en) 2020-12-02 2022-06-09 Glaxosmithkline Biologicals Sa Novel antigens
WO2022162012A2 (en) 2021-01-26 2022-08-04 Eth Zurich Antibodies broadly targeting coronaviruses and uses thereof
WO2022161598A1 (en) 2021-01-26 2022-08-04 Eth Zurich Antibodies broadly targeting coronaviruses and uses thereof
EP4469078A1 (en) 2022-01-28 2024-12-04 GlaxoSmithKline Biologicals S.A. Modified human cytomegalovirus proteins

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61227586A (ja) * 1985-03-30 1986-10-09 Dai Ichi Seiyaku Co Ltd ジサツカライド誘導体およびその塩
US4746742A (en) * 1985-11-28 1988-05-24 Toho Yakuhin Kogyo Kabushiki Kaisha Analogs of nonreducing monosaccharide moiety of lipid A
JPS62129292A (ja) * 1985-11-28 1987-06-11 Toho Yakuhin Kogyo Kk 生物活性を発現するリピドa単糖類縁体
JPH0426662A (ja) * 1990-05-23 1992-01-29 Tosoh Corp アミノ酸アシル誘導体及びその製造法
DE4229877C2 (de) * 1992-09-04 1994-09-15 Max Delbrueck Centrum Phospho- bzw. Phosphono-(N-acyl)-serine und ihre Herstellung
JPH06206893A (ja) * 1992-09-07 1994-07-26 Suntory Ltd 新規なジサッカライド誘導体
EP0668289A4 (en) * 1993-09-07 1998-10-21 Suntory Ltd NEW DISACCHARIDE DERIVATIVE.
PL181241B1 (pl) * 1993-11-17 2001-06-29 Deutsche Om Arzneimittel Gmbh Disacharydy beta(1 6)glukozoaminowe, sposób wytwarzania disacharydu beta(1 6) glukozoaminowego, zawierająca je kompozycja farmaceutyczna i środek immunomodulujący i/lub przeciwnowotworowy oraz szczepionka
HUP0102475A3 (en) * 1998-06-30 2001-12-28 Om Pharma Novel acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same

Also Published As

Publication number Publication date
AU761396B2 (en) 2003-06-05
KR20010083078A (ko) 2001-08-31
BR9911329A (pt) 2001-10-16
EE200000791A (et) 2002-02-15
US20060148678A1 (en) 2006-07-06
RU2223262C2 (ru) 2004-02-10
JP4699609B2 (ja) 2011-06-15
SK287073B6 (sk) 2009-11-05
US7157092B1 (en) 2007-01-02
ATE355266T1 (de) 2006-03-15
DE69935330T2 (de) 2007-10-31
HUP0102475A3 (en) 2001-12-28
SK18872000A3 (sk) 2001-07-10
DK1091928T3 (da) 2007-07-23
CZ302062B6 (cs) 2010-09-22
WO2000000462A1 (fr) 2000-01-06
DE69935330D1 (de) 2007-04-12
TWI255808B (en) 2006-06-01
CN1306504A (zh) 2001-08-01
ES2284275T3 (es) 2007-11-01
CZ20004893A3 (en) 2001-05-16
PL195764B1 (pl) 2007-10-31
AU4284899A (en) 2000-01-17
JP2002519338A (ja) 2002-07-02
AR029877A1 (es) 2003-07-23
CN1168702C (zh) 2004-09-29
PL345040A1 (en) 2001-11-19
HUP0102475A2 (hu) 2001-11-28
CA2337807A1 (fr) 2000-01-06
EP1091928A1 (fr) 2001-04-18
CA2337807C (fr) 2012-08-21
KR100766016B1 (ko) 2007-10-11
EP1091928B1 (fr) 2007-02-28

Similar Documents

Publication Publication Date Title
EE04489B1 (et) Atsüülpseudodipeptiidid, nende valmistamise meetod ja neid sisaldavad farmatseutilised kompositsioonid
EE200000707A (et) Oksasolidinooni derivaadid, nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid
EE04498B1 (et) Erütromütsiini derivaadid, nende valmistamismeetod ja neid sisaldav farmatseutiline kompositsioon
EE200000168A (et) Karboksamidotiasoolderivaadid, nende valmistamine ja neid sisaldavad farmatseutilised kompositsioonid
EE04779B1 (et) 1,3-dihüdro-2H-indool-2-ooni derivaadid, nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid
EE04673B1 (et) Kinoliini derivaadid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad farmatseutilised kompositsioonid
EE03929B1 (et) Sünteetilised polüsahhariidid, nende valmistamisemeetod ja neid sisaldavad farmatseutilised kompositsioonid
FI973148A7 (fi) Substituoituja heterosyklisiä yhdisteitä, menetelmä niiden valmistamis eksi ja niitä sisältäviä farmaseuttisia koostumuksia
EE9700333A (et) Substitueeritud 4-fenüülaminotiasoolid, nende valmistamise meetod ja neid sisaldavad farmakoloogilised kompositsioonid
EE04276B1 (et) Kinoliini derivaadid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad farmatseutilised kompositsioonid
FI952550A7 (fi) Uudet N-pyridyylikarboksamidit ja johdannaiset, menetelmät niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
EE9800426A (et) Asendatud 2,4-tiasolidiindiooni derivaadid, nende valmistamismeetodid ja neid sisaldavad farmatseutilised kompositsioonid
FI950625A7 (fi) Polysubstituoituja 3-asyyliamino-5-fenyyli-1,4-bentsodiatsepiini-2-onijohdannaisia, menetelmä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia
EE200000429A1 (et) Sünteetilised polüsahhariidid, nende valmistamismeetodid ja neid sisaldavad farmatseutilised kompositsioonid
EE03395B1 (et) Bensotiasolooni derivaadid, protsessid ja kasutatud vaheühendid nende saamiseks ning neid sisaldavad ravimkoostised
EE200000421A (et) Uued pentasahhariidid, nende valmistamismeetodid ja neid sisaldavad farmatseutilised kompositsioonid
EE9800264A (et) Taksoidid, nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid
FI956278A7 (fi) Substituoituja 4-fenyylitiatsolijohdannaisia, menetelmä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia
FI950817A7 (fi) Uudet bentsodioksaaniyhdisteet, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
FI960316L (fi) Oksatiolaanit, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
FI955085L (fi) Uudet diosmetiiniyhdisteet, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
EE04778B1 (et) Hargnenud ahelaga asendatud 3-amino-1-fenüül-1H-[1,2,4]triasooli aminoderivaadid, nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid
EE03996B1 (et) Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine
FI951091L (fi) Uudet alkyyliaminoindaaniyhdisteet, menetelmät niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
EE200100499A (et) Uued morfoliini derivaadid, nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20130623